Abstract
In the management of leukemia and malignant solid tumors [if one excepts the graft-versus-leukemia (GVL) effect of an allograft], bone marrow transplantation (BMT) is not therapeutic per se, but is simply a method designed to overcome myelotoxicity after high-dose chemotherapy. The main limitations of this method are graft-versus-host disease (GVHD) in allogenic BMT and the contamination of the graft by residual malignant cells in autologous BMT. A common approach, so-called purging, has been proposed to eliminate unwanted cells from the BM before its reinjection—either allogenic normal T cells responsible for GVHD or autologous malignant cells.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
DeWitte T, Hoogenhout J, De Pauw B, Holdrinet R, Jansen J, Wessels J, Van Daal W, Hustinx K, Haanen C (1986) Depletion of donor lymphocytes by counterflow centrifugation successfully prevents acute graft-versus-host disease in matched allogeneic marrow transplantation. Blood 67: 1302
Reisner Y, Kapoor D, Kirkpatrick D, Pollack MS, Cunningham-Rundles S, Dupont B, Hodes MZ, Good RA, O’Reilly RJ (1983) Transplantation for severe combined immunodeficiency with HLA-A, B, D, DR incompatible parental marrow cells fractionated by soybean agglutinin and sheep red blood cells. Blood 61: 341
Reisner Y (1983) Differential agglutination by soybean agglutinin of human leukemia and neuroblastoma cell lines: potential application to autologous bone marrow transplantation. Proc Natl Acad Sci USA 80: 6657
Korbling M, Hess AD, Tutschka PJ, Kaiser H, Colvin MO, Santos GW (1987) 4hydroperoxycyclophosphamide: a model for eliminating residual human tumour cells and T-lymphocytes from the bone marrow graft. Br J Haematol 52: 89
Kluin-Nelemans HC, Martens ACM, Lowenberg B, Hagenbeek A (1984) No preferential sensitivity of clonogenic AML cells to Asta Z 7557. Leuk Res 8: 723
Yeager AM, Kaizer J, Santos GW, Saral R, Colvin OM, Stuart RK, Braise HG, Burke PJ, Ambinder RF, Burns WH (1986) Autologous bone marrow transplantation in patient with acute non-lymphocytic leukemia, using ex vivo marrow treatment with 4-hydroperoxycyclophosphamide. N Engl J Med 315: 141
Gorin NC, Douay L, Laporte JP, Lopez M, Mary JY, Najman A, Salmon C, Aagerter P, Stachowiak J, David R, Pene F, Kantor G, Deloux J, Duhamel E, Van den Akker J, Gerota J, Parlier Y, Duhamel G (1986) Autologous bone marrow transplantation using marrow incubated with Asta Z 7557 in adult acute leukemia. Blood 67: 1367
Hervé P, Cahn JV, Plouvier E, Flesch M, Tamayo E, Leconte des Floris R, Peters A (1984) Autologous bone marrow transplantation for acute leukemia using transplant chemopurified with metabolite of oxazaphosphorines (ASTA Z 7557, INN mafosfamide). First clinical results. New Drugs 2: 245
Kaizer H, Stuart RK, Brookmeyer R, Beschorner WE, Braine HG, Burns WH, Fuller DJ, Korbling M, Mangan KF, Saral R, Sensenbrenner L, Shadduck RK, Shende AC, Tutschka PJ, Yeager AM, Zinkham WH, Colvin OM, Santos GW (1985) Autologous bone marrow transplantation in acute leukemia: a phase I study of in vitro treatment of marrow with 4hydroperoxycyclophosphamide to purge tumor cells. Blood 65: 1504
Hartmann O, Kalifa C, Beaujean F, Bayle C, Benhamou E, Lemerle J (1985) Treatment of advanced neuroblastoma with two consecutive high-dose chemotherapy regimens and ABMT. In: Evans AE, D’Angio O, Seeger RC (eds) Advances in neuroblastoma research. Alan R, iss, New York, pp 565–568
Chang TT, Gulati SC, Chou TC, Vega R, Gandola L, Ezzat Ibrahim SM, Yopp J, Colvin M, Clarkson BD (1985) Synergistic effect of 4-hydroperoxycyclophosphamide and etoposide on a human promyelocytic leukemia cell line (HL-60) demonstrated by computer analysis. Cancer Res 45: 2434
Sieber F, Spivak JL, Sutcliffe AM (1984) Selective killing of leukemic cells by merocyanine 540-mediated photosensitization. Proc Natl Acad Sci USA 81: 7584
Reynolds CP, Reynolds DA, Frenkel EP, Graham Smith R (1982) Selective toxicity of 6hydroxydopamine and ascorbate for human neuroblastoma in vitro: a model for clearing marrow prior to autologous transplant. Cancer Res 42: 1331
Lebien TW, Stepan DE, Bartholomew RM, Stong RC, Anderson JM (1985) Utilization of a colony assay to assess the variables influencing elimination of leukemic cells from human bone marrow with monoclonal antibodies and complement. Blood 65: 945
Lebien TW, Stepan DE, Bartholomew RM, Stong RC, Anderson JM (1985) Utilization of a colony assay to assess the variables influencing elimination of leukemic cells from human bone marrow with monoclonal antibodies and complement. Blood 65: 945
Bast RC, De Fabriities P, Lipton J, Gelber R, Mayer C, Nadler L, Sallan S, Ritz J (1985) Elimination of malignant clonogenic cells from human bone marrow using multiple monoclonal antibodies and complement. Cancer Res 45: 499
Favrot MC, Philip I, Philip T, Pinkerton R, Lebacq AM, Forster K, Adeline P, Doré JF (1986) Bone marrow purging procedure in Burkitt lymphoma with monoclonal antibodies and complement. Quantification by a liquid cell culture monitoring system. Br J Cancer 64: 161
Waldman H, Hale G, Cividalli G, Weshler Z, Manor D, Rachmilewitz EA, Polliak A, Or R, Weiss L, Samul S, Brautbar C, Slavin S (1984) Elimination of graft-versus-host disease by in vitro depletion of alloreactive lymphocytes with a monoclonal rat anti-human lymphocyte antibody (Campath-1). Lancet 2: 483
Stepan DE, Bartholomew RM, Lebien TW (1984) In vitro cytodestruction of human leukemic cells using murine monoclonal antibodies and human complement. Blood 63: 1120
Saarinenu M, Coccia PF, Gerson SL, Pelley R, Cheung NKV (1985) Eradication of neuroblastoma cells in vitro by monoclonal antibody and human complement: method for purging autologous bone marrow. Cancer Res 45: 5969
Treleaven JG, Gibson FM, Ugelstad J, Rembaum A, Philip T, Caine GD, Kemshead JT (1984) Removal of neuroblastoma cells from bone marrow with monoclonal antibodies conjugated to magnetic microspheres. Lancet 14: 70
Favrot MC, Philip I, Combaret V, Maritaz O, Philip T (1987) Experimental evaluation of an immunomagnetic bone marrow purging procedure using the Burkitt lymphoma model. Bone Marrow Transplantation 2: 56–59
Combaret V, Favrot MC, Kremens B, Laurent JC, Philip I, Philip T (1987) Elimination of Burkitt cells from excess bone marrow with an immunomagnetic purging procedure. Selection of monoclonal antibodies is a critical step. In: Proceedings of the Third International Symposium on ABMT, Houston, pp 443–448
Reynolds PC, Seeger RC, Vo DD, Black AT, Wells J, Ugelstad J (1986) Model system for removing neuroblastoma cells from bone marrow using monoclonal antibodies and magnetic immunobeads. Cancer Res 46: 5882
Poynton CH, Dicke KA, Culbert S, Frankel LS, Jagannath S, Reading CL (1983) Immumomagnetic removal of CALLA positive cells from human bone marrow. Lancet 1: 524
Berenson RJ, Bensinger WI, Kalamasz D, Martin P (1986) Elimination of Daudi lymphoblasts from human bone marrow using avidin-biotin immunoadsorption. Blood 67: 509
Filipovich AH, Vallera DA, Youle RJ, Quinones RR, Neville DM, Kersey JH (1984) Ex-vivo treatment of donor bone marrow with anti-T cell immunotoxins for prevention of graft-versushost disease. Lancet 1: 469
Casellas P, Canat X, Fauser AA, Gros O, Laurent G, Poncelet P, Jansen FK (1985) Optimal elimination of leukemic T cells from human bone marrow with T101-ricin A chain immunotoxin. Blood 65: 289
Stong RC, Youle RJ, Vallera DA (1984) Elimination of clonogenic T-leukemic cells from human bone marrow using anti-Mr 65,000 protein immunotoxins. Cancer Res 44: 3000
Myers CD, Thorpe PE, Ross WCJ, Cumber AJ, Katz FE, Tax W, Greaves MF (1984) An immunotoxin with therapeutic potential in T cell leukemia: WT1-Ricin A. Blood 63: 1178
Muirhead M, Martin PJ, Torok-Storb B, Uhr JW, Vitetta ES (1983) Use of an antibody-ricin A-chain conjugate to delete neoplastic B cells from human bone marrow. Blood 62: 327
Coombes RC, Buckman R, Forster JA, Shepherd V, O’Hare MJ, Vincent M, Powles TJ, Neville AM (1986) In vitro and in vivo effects of a monoclonal antibody-toxin conjugate for use in autologous bone marrow transplantation for patients with breast cancer. Cancer Res 46: 4217
Uckun FM, Ramakrishnan S, Houston LL (1985) Increased efficiency in selective elimination of leukemia cells by a combination of stable derivative of cyclophosphamide and a human B-cellspecific immunotoxin containing pokeweed antiviral protein. Cancer Res 45: 69
Ramakrishnan S, Houston LL (1984) Inhibition of human acute lymphoblastic leukemia cells by immunotoxins: potentiation by chloroquine. Science 223: 58
Bjorn MJ, Groetsema G, Scalapino L (1986) Antibody-pseudomonas exotoxin A conjugates cytotoxic to human breast cancer cells in vitro. Cancer Res 46: 3262
Janossy G, Prentice HG, Grob JP, Ivory K, Tidman N, Grundy J, Favrot M, Brenner MK, Campana D, Blacklock HA, Gilmore MJML, Patterson J, Griffiths PD, Hoffbrand AV (1986) T lymphocyte regeneration after transplantation of T cell depleted allogeneic bone marrow. Clin Exp Immunol 63: 577
Fischer A, Griscelli C, Blanche S, Le Deist F, Veber F, Lopez M, Delaage M, Olive D, Mawas C, Janossy G (1986) Prevention of graft failure by an anti-HLFA-1 monoclonal antibody in HLA-mismatched bonemarrow transplantation. Lancet 2: 1058
Thierfelder S, Rodt H, Netzel B (1977) Transplantation of syngeneic bone marrow incubated with leucocyte antibodies. Transplantation 23: 459
Hagenbeek A, Van Bekkum DW (eds) (1977) Proceedings of an International Workshop on comparative evaluation of the L5222 and the BNML rat leukemia models and their relevance for human acute leukemia. Leuk Res 1: 75–78
Reynolds CP, Black AT, Woody JN (1986) Sensitive method for detecting viable cells seeded into bone marrow. Cancer Res 46: 5878
Philip I, Favrot MC, Philip T (1987) Use of a liquid cell culture assay to quantify the elimination of Burkitt lymphoma cells from the bone marrow. J Immunol Methods 97: 11
Ajani JA, Spitzer G, Tomasovic B, Drewinko B, Hug VM, Dicke K (1986) In vitro cytotoxicity patterns of standard and investigational agents on human bone marrow granulocyte-macrophage progenitor cells. Br J Cancer 54: 607
Uckun FM, Gajil-Peczalska KJ, Kersey JH, Houston LL, Vallera DA (1986) Use of a novel colony assay to evaluate the cytotoxicity of an immunotoxin containing pokeweed antiviral protein against blast progenitor cells freshly obtained from patients with common B-lineage acute lymphoblastic leukemia. J Exp Med 163: 347
Campana D, Janossy G (1986) Leukemia diagnosis and testing of complement fixing antibodies for bone marrow purging in acute lymphoid leukemia. Blood 68: 1264–1271
Moss TJ, Seeger RC, Kindler-Rohrborn A, Marangos PJ, Rajevsky MF, Reynolds CP (1985) Immunohistologic detection and phenotyping of neuroblastoma cells in bone marrow using cytoplasmic neuron specific enolase and cell surface antigens. In: Evans AE, d’Angio O, Seeger RC (eds) Advances in neuroblastoma research. Alan R Liss, New York, p 367
Philip I, Philip T, Favrot MC, Vuillaume M, Fontanière B, Chamard D, Lenoir GM (1984) Establisment of lymphomatous cell lines from bone marrow samples from patients with Burkitt’s lymphoma. JNCI 73: 835
Philip I, Favrot MC, Combaret V, Laurent JC, Kremens B, Philip T (1986) Use of a liquid cell culture assay to measure the in vitro elimination of Burkitt’s cells from the BM in preclinical and clinical procedures. In: Proceedings of the Third International Symposium on ABMT, Houston, pp 351–358
Philip T, Bernard JL, Zucker JM, Pinkerton R, Lutz P, Bordigoni P, Plouvier E, Robert A, Carton R, Philippe N, Philip I, Favrot MC (1987) High dose chemotherapy with bone marrow transplantation as consolidation treatment in neuroblastoma: an unselected group of stage IV patients over one year of age. J Clin Oncol 5: 266
De Fabriitis P, Bregni M, Lipton J, Greenberger J, Nadler L, Rothstein L, Korbling M, Ritz J, Bast RC (1985) Elimination of clonogenic Burkitt’s lymphoma cells from human bone marrow using 4-hydroperoxycyclophosphamide in combination with monoclonal antibodies and cornplement. Blood 5: 1064
Lebien TW, Anderson JM, Vallera DA, Uckun FM (1986) Increased efficacy in selection elimination of leukemic cell line clonogenic cells by a combination of monoclonal antibodies BA-1, BA-2, BA-3 plus complement and mafosfamid (ASTA Z 7557). Leuk Res 10: 139
Favrot MC, Philip I, Poncelet P, Combaret V, Kremens B, Janossy G, Philip T (1987) Comparative efficiency of an immunomagnetic procedure and a rabbit complement lysis for eliminating BL cells from the bone marrow. In: Proceedings of the Third International symposium on ABMT, Houston, pp 359–364
Chang J, Coutinho L, Morgenstein G, Scarffe JH, Deakin D, Harrison C, Testa NG, Dexter TM (1986) Reconstitution of haemopoietic system with autologous marrow taken during relapse of acute myeloblastic leukaemia and grown in long-term culture. Lancet 1: 294
Berenoson RJ, Andrews RG, Bensinger WI, Kalamasz D, Knitter G, Bernstein ID (1986) In vivo reconstitution of hematopoiesis in baboons using 12.8 positive marrow cells isolated by avidin-biotin immunoadsorption (Abstr 1025). Blood 68: 287
To LB, Haylock DN, Kimber RJ, Juttner CA (1984) High levels of circulating haematopoiesis stem cells in very early remission from acute non-lymphoblastic leukaemia and their collection and cryopreservation. Br J Haematol 58: 399
Rosenberg SA, Lotze MT, Muul LM, Leituran S, Chang AE, Ettinghausen SE, Matory YL, Skibber JM, Shiloni E, Vetto JT, Seipp GA, Simpson C, Reichert CM (1985) Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med 313: 1485
O’Reilly RJ, Kernan N, Collins N, Brochstein J, Cunningham I, Castro-Malaspina H, Laver J, Emanuel D, Gulati S, Flomenberg N, Keever C (1986) Abrogation of both acute and chronic GVHD following transplants of lectin agglutinated, E-rosette depleted (SBA-E-) marrow for leukemia (Abstr 1041). Blood 68: 291
Prentice HG, Janossy G, Price-Jones L, Tregdosiewicz LK, Panjwani DI, Graphokos S, Ivory K, Blacklock HA, Gilmore MJ, Tidman N, Skeggs DBL, Ball S, Patterson J, Hoffbrand AV (1984) Depletion of T-lymphocytes in donor marrow prevents significant graft versus host disease in matched allogeneic leukaemic marrow transplant recipients. Lancet 1: 472
Martin PJ, Hansen JA, Buckner CD, Sanders JE, Deeg HJ, Stewart P, Appelbaum FR, Clift R, Fefer A, Witherspoon RP, Kennedy MS, Sullivan KM, Flournoy N, Storb R, Thomas ED (1985) Effects of in vitro depletion of T cells in HLA-identical allogeneic marrow grafts. Blood 66: 664
Hervé P, Cahn JY, Flesch M, Plouvier E, Racadot E, Noir A, Couteret Y, Goldstein G, Bernard A, Lenys R, Bresson JL, Leconte des Floris R, Peters (1987) Successful GVHD prevention without graft failure in 32 HLA-identical allogeneic bone marrow transplantations with marrow depleted of T-cells by monoclonal antibodies and complement. Blood 69: 388–393
Racadot E, Hervé P, Beaujean F, Vernant JP, Flesch M, Plouvier E, Andreu G, Rio B, Philippe N, Souillet G, Pico J, Bordigoni J, Ifrah N, Paitre ML, Lutz P, Morizet J, Bernard A (1986) Prevention of graft versus host disease in HLA matched bone marrow transplantation for malignant diseases. A multicentric study of 62 patients using 3 pan-T monoclonal antibodies and rabbit complement. J Clin Oncol 5: 426–435
Quinones RR, Youle RJ, Kersey JH, Zanjani ED, Azemove SM, Soderling CCB, Lebien TW, Beverley PCL, Neville DM, Vallera DA (1984) Anti-T cell monoclonal antibodies conjugated to ricin as potential reagents for human GVHD prophylaxis: effect on the generation of cytotoxic T cells in both peritoneal blood and bone marrow. J Immunol 132: 1322
Kemshead JT, Heath L, Gibson FM, Katz F, Richmond F, Treleaven J, Ugelstad J (1986) Magnetic microspheres and monoclonal antibodies for the depletion of neuroblastoma cells from bone marrow: experiences, improvements and observations. Br J Cancer 54: 771
Seeger RC, Wells J, Lenarsky C, Feig SA, Selch M, Moss TJ, Ugelstad J, Reynolds CP (1986) Bone marrow transplantation for poor prognosis neuroblastoma (Abstr 20). J Cell Biochem 10D: 215
Douay L, Gorin NC, Laporte JP, Lopez M, Najman A, Duhamel G (1984) ASTA Z 7557 ( INN mafosfamide) for the in vitro treatment of human leukemic bone marrows. Invest New Drugs 2: 187
Bast RC Jr, Sallan SE, Reynolds C, Lipton J, Ritz J (1985) Autologous bone marrow transplantation for CALLA-positive acute lymphoblastic leukemia: an update. In: Dicke KA, Spitzer G, Zander AR (eds) Autologous bone marrow transplantation. ND Anderson Hospital, Houston, pp 3–6
Ramsay N, Lebien TW, Nesbit M, McGlave P, Weisdorf D, Kenyon P, Hurd D, Goldman A, Kim T, Kersey (1985) Autologous bone marrow transplantation for patients with acute lymphoblastic leukemia in second or subsequent remission. Results of bone marrow treated with monoclonal antibodies BA-1, BA-2 and BA-3 plus complement. Blood 66: 508
Nadler LM, Takvorian T, Botnick L, Bast RC, Finberg R, Hellman S, Canellos GP, Schlossman SF (1984) Anti-B1 monoclonal antibody and complement treatment in autologous bone marrow transplantation for relapsed B-cell non-Hodgkin’s lymphoma. Lancet 2: 427
Philip T, Biron P, Philip I, Favrot M, Souillet G, Frazppaz D, Jaubert J, Bordigoni P, Bernard JL, Laporte JP, Le Mevel A, Plouvier E, Marguerite G, Pinkerton R, Brizard CP, Freycon F, Forster HK, Philippe N, Brunat-Mentigny M (1986) Massive therapy and autologous bone marrow transplantation in pediatric and young adults Burkitt’s lymphoma (30 courses in 28 patients: a 5-year experience). Eur J Cancer Clin Oncol 22: 1015
Baumgartner C, Brun del Re G, Forster HK, Bucher U, Delaveu B, Hirt A, Imbach P, Luthy A, Stern AC, Wagner HP (1985) Autologous bone marrow transplantation for pediatric non-Hodgkin’s lymphoma: in vitro purging of the graft with anti-Y29/55 monoclonal antibody and complement. In: Dicke KA, Spitzer G, Zander AR (eds) Autologous bone marrow transplantation. ND Anderson Hospital, Houston, pp 377–381
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1989 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Favrot, M.C., Philip, T. (1989). Bone Marrow Purging. In: Magrath, I. (eds) New Directions in Cancer Treatment. UICC International Union Against Cancer. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-83405-9_18
Download citation
DOI: https://doi.org/10.1007/978-3-642-83405-9_18
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-19063-9
Online ISBN: 978-3-642-83405-9
eBook Packages: Springer Book Archive